D-0515-2026 Class II Ongoing

Recalled by Ajanta Pharma Ltd. — Aurangabad

FDA drug recall D-0515-2026 was initiated by Ajanta Pharma Ltd. on Apr 29, 2026 and is designated Class II. Reason for recall: CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals. The recall status is ongoing. Affected quantity: 77,376 packs.

Recall details

Product Type
Drugs
Report Date
May 13, 2026
Initiation Date
Apr 29, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
77,376 packs.

Product description

Duloxetine Delayed-Release Capsules, 60 mg, Rx Only, 30 capsules, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-099-03

Reason for recall

CGMP Deviations: Presence of N-nitroso-Duloxetine impurity above FDA recommended limit of 0.83 ppm, identified at the 12-month and 18-month long-term stability intervals.

Distribution pattern

Nationwide within U.S

Code information

Lot#: PA07434, Exp. May 2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0515-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0515-2026. Report a data issue: hello@regdatalab.com.